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LETTER TO THE EDITOR
Dear Sir,
Long-term survival from uterine cervical cancer in Mumbai (Bombay), India
Hospital- and population-based results on survival from
cancer are available from only very few regions in the develop-
ing world, and this information concerns a maximum of 5 years
after diagnosis only (Nandakumar et al., 1995; Sriamporn et
al., 1995; Sankaranarayanan et al., 1995, 1996; Jayant et al.,
1996). There are no reports on long-term survival (10 or 15
years after diagnosis) from cancer in developing countries. This
brief report concerns long-term survival from cervical cancer
in Mumbai (Bombay), India.
Cases of cervical cancer (n 5 378) were registered for the
year 1977 in the population-based cancer registry of Bombay,
and survival of 331 was studied after excluding 47 cases
registered on the basis of death certificate only (DCO). The
distribution of histology was as follows: squamous cell carci-
noma, 302; adenocarcinoma, 15; adeno-squamous carcinoma,
3; others, 2; histology not available, 9. The stage distribution of
patients was as follows: stage I, 63 cases; II, 96; III, 118; IV, 52.
Staging details were not available in 2 cases. Staging was based
on the FIGO classification. Treatment details were as follows:
167 patients received radiotherapy; 36 were treated with sur-
gery; 35 had surgery plus radiotherapy; 6 had chemotherapy in
addition to surgery and/or radiotherapy; and for 87 cases
treatment details either were not available or the subjects
received no treatment.
The cutoff date for follow-up was 31 December 1993. Both
active and passive methods were used to obtain information on
the vital status of cases. Incident cases were matched with death
certificates mentioning cancer or tumour as cause of death up
to 1995. For unmatched cases, reply-paid postal enquiries were
made. For those patients who did not reply, home visits were
carried out. Where home visits were not successful, the case
records were scrutinized from reporting hospitals whenever
possible for last visit and vital status.
The survival time for each case was the duration between the
date of incidence and the date of death or of last follow-up.
Cumulative observed survival rates were calculated by the
Kaplan and Meier (1958) method. Cumulative relative survival
rates were calculated as a ratio of observed and expected
survival rates (Parkin and Hakulinen, 1991). The expected
survival for a group of people in the general population similar
to the patient population with respect to age, sex and calendar
period of observation was calculated using the Bombay life
table.
The overall 5-, 10- and 15-year observed survival rates were
51.0%, 36.3% and 30.0% respectively; the corresponding rela-
tive survival rates were 54.8%, 43.0% and 41.1% respectively.
Table I shows observed and relative survival by age group, and
Figure 1 shows the stage-specific observed survival rates.
There was a clear downward gradient in survival with advanc-
ing clinical stage of the disease. The 15-year stage-specific
survival rates for cervical cancer were as follows: stage I,
79.2%; stage II, 29.2%; stage III, 11.6%. There were no
long-term survivors in the stage IV category.
The 5-year survival reported in our study is comparable
with other published results from India and from other
developing countries (Nandakumar et al., 1995; Sriamporn et
al., 1995; Sankaranarayanan et al., 1995, 1996; Jayant
et al., 1996). However, these are lower than the population-
based survival rates reported for cervical cancer (all ethnic
groups) from the SEER (Surveillance, Epidemiology,
and End Results) programme of the United States (Ries et al.,
1997) and the European registries (Berrino et al., 1995). For
instance, the 5-, 10- and 15-year relative survival rates for
cervical cancers registered in SEER during 1977 were 69.4%,
66.1% and 64.5% respectively; the 5- and 10-year relative
survival rates observed in a weighted analysis of data
from registries in 12 European countries were 59% and 55%,
respectively.
In spite of the possibility of some misclassification in staging,
the long-term survival from early cervical cancer is impressive
and indicates that a significant reduction in mortality from
cervical cancer could be achieved by early detection and
treatment. Gains in 5-year survival have been demonstrated
from a rural area of India following earlier detection as a result
of improved awareness and motivation (Jayant et al., 1995,
1996). The trend towards diagnosis in earlier stages and the
improvement in survival outcome from cervical cancer in Swe-
den before the introduction of widespread cervical cytology
screening provide further observational evidence of the effective-
ness of increased awareness linked with facilities for diagnosis
and treatment in the control of cervical cancer (Ponte´n et al.,
1995). It will not be possible to implement organised cervical
cytology programmes to control cervical cancer in developing
countries for many years, if ever. The performance of unaided
visual inspection (clinical down-staging), without the applica-
tion of acetic acid, involving naked-eye speculum examination
of the uterine cervix, is not satisfactory for detecting lesions,
particularly pre-invasive lesions (Sankaranarayanan et al.,
1997). It is likely that the magnitude of stage shift anticipated
by active case finding with clinical down-staging may be
achieved by both improving the awareness of and motivating
the public and medical profession. While there is an urgent need
to address a feasible and effective alternative to cytology
screening with the objective of prevention of invasive cervical
cancer, our results and other reports call for sincere efforts to
improve awareness among the public and the profession by
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educational measures as a means to reduce mortality from this
cancer in developing countries.
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TABLE I – SURVIVAL FROM CERVICAL CANCER BY AGE GROUP
Age
group
(years)
Observed survival Relative survival
1-year 5-year
10-
year
15-
year
1-
year
5-
year
10-
year
15-
year
,34 (n 5 28) 71.6 60.1 45.1 45.1 71.8 61.0 46.5 47.5
35–44
(n 5 96)
86.3 65.5 49.4 42.5 86.6 65.9 52.1 47.0
45–54
(n 5 113)
77.6 45.8 28.0 24.1 78.2 47.9 31.4 30.0
55–64
(n 5 55)
70.9 56.0 40.7 — 72.3 62.2 52.9 —
65–74
(n 5 33)
69.0 27.9 23.3 — 72.6 36.7 47.0 —
751 (n 5 6) 80.0 20.0 — — 88.9 33.9 — —
All ages
(n 5 331)
77.7 51.0 36.3 30.0 78.8 54.8 43.0 40.1
FIGURE 1 – Observed survival from cervical cancer by clinical
stages in Mumbai (Bombay), India.
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